Stock AnalizNeurocrine Biosciences Inc. NBIX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 1996 · data as of November 13, 2026
Neurocrine Biosciences Inc. (NBIX) is a healthcare company listed in the US with a market value of about $16.9B. In the twelve months to September 30, 2026 it had revenue of $3.7B and net income of $702M, a net margin of 19.0%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is future growth (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 24.8, a price to free cash flow of 16.3, 5-year revenue growth of 22% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 53% above the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below the industry median
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788M | $451M | $162M | $15M |
| Net income | $702M | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | -$143M | -$141M |
| Free cash flow | $1.0B | $749M | $557M | $362M | $323M | $233M | $218M | $132M | $77M | -$101M | -$110M |
| EPS (diluted) | $6.74 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
| Net margin | 19.0% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% |
| ROIC | — | 11.3% | 13.0% | 7.5% | 9.9% | 5.0% | 8.3% | 7.9% | 4.1% | -17.7% | -46.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 28 analysts is $208.11, 24% above the current price; targets range from $150.00 to $253.00; the consensus rating is “Strong buy”; expected EPS is $10.59 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Neurocrine Biosciences’s P/E ratio?
About 24.8, based on the last twelve months of diluted earnings per share (forward P/E about 14.4).
Is Neurocrine Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 53% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Neurocrine Biosciences pay a dividend?
Not currently.
Is Neurocrine Biosciences a good stock to buy?
We do not give buy or sell advice. Neurocrine Biosciences scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.